Clinical data
Routes of
Oral, intranasal, bucal, sublingual, intravenous
ATC code none
Legal status
Legal status
  • AU: ?
  • CA: ?
  • UK: ?
  • US: not scheduled
Pharmacokinetic data
Biological half-life ?
Synonyms mescaline-NBOMe; 345-NBOMe; N-(2-methoxybenzyl)-3,4,5-trimethoxyphenethylamine; 2-(3,4,5-trimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; 3,4,5-Trimethoxy-N-(2-methoxybenzyl)phenethylamine
CAS Number 1354632-01-1 YesY
PubChem (CID) 57501069
ChemSpider 25949200 YesY
Chemical and physical data
Formula C19H25NO4
Molar mass 331.4061 g/mol
3D model (Jmol) Interactive image

NBOMe-mescaline or mescaline-NBOMe is a synthetic substituted phenethylamine. It is a partial agonist of serotonin receptors with preference for 5-HT2A over 5-HT2C (EC50 = 4 and 24 μM, respectively).[1]


NBOMe-mescaline was first reported in the scientific literature in 1997 as a serotonin receptor agonist in the Journal of Medicinal Chemistry.[1] NBOMe-mescaline and NBOMe-escaline were reported in 1999 resulting from research performed at Free University of Berlin concerning their activity as partial agonists at rat vascular 5-HT2A receptors.[2] NBOMe-mescaline was first reported in September 2008 to have been self administered by humans as a psychedelic drug at some unspecified point prior.[3] It first became available as a commodity in the research chemical market in May 2010 several months after a few 25x-NBOMes became available.

Properties and chemistry

Solubility of the hydrochloride salt: ~5 mg/ml in Phosphate Buffered Saline (PBS) @ pH 7.2; ~10 mg/ml in ethanol & DMF; ~20 mg/ml in DMSO.[4]


NBOMe-mescaline can be synthesized from mescaline and 2-methoxybenzaldehyde, via reductive alkylation. That can be done stepwise by first making the imine and then reducing the formed imine with sodium borohydride, or by direct reaction with sodium triacetoxyborohydride. An alternative production method which removes the need to obtain the illegal compound mescaline as an isolated precursor can be achieved via a one-pot reaction utilizing 3,4,5-trimethoxyphenylacetonitrile with Lithium Aluminium Hydride as a reducing agent.

Psychedelic dosage in humans

There have been very few reports of human use of NBOMe-mescaline. Psychedelic visual, auditory and mental effects start around 50 mg intranasally.[5]

NBOMe-mescaline is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971.[6]

United States

NBOMe-mescaline is not listed in the list of scheduled controlled substances in the USA.[7] It is therefore not scheduled at the federal level in the United States, but it is possible that NBOMe-mescaline could legally be considered an analog of mescaline and sales or possession could potentially be prosecuted under the Federal Analogue Act.[8]

See also


This article is issued from Wikipedia - version of the 11/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.